The TOLEDO study provides new evidence to support the use of subcutaneous apomorphine infusion to control motor fluctuations in patients with advanced Parkinson disease. The findings should encourage neurologists to consider implementing apomorphine infusion or other device-aided therapies earlier in the disease course, before the emergence of troublesome dyskinesias.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Current and novel infusion therapies for patients with Parkinson's disease
Journal of Neural Transmission Open Access 06 September 2023
-
Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity
Scientific Reports Open Access 07 December 2022
-
Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway
Cellular and Molecular Neurobiology Open Access 20 August 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Antonini, A. et al. Medical and surgical management of advanced Parkinson’s disease. Mov. Disord. 33, 900–908 (2018).
Antonini, A. et al. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 24, 119–129 (2010).
Iravani, M. M., McCreary, A. C. & Jenner, P. Striatal plasticity in Parkinson’s disease and L-dopa induced dyskinesia. Parkinsonism Relat. Disord. 18, S123–S125 (2012).
Jenner, P. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson’s disease. Neurol. Clin. 31, S17–S35 (2013).
Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749–759 (2018).
Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13, 141–149 (2014).
Antonini, A. et al. Effect of levodopa–carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov. Disord. 31, 530–537 (2016).
Schuepbach, W. M. et al. Neurostimulation for Parkinson’s disease with early motor complications. N. Engl. J. Med. 368, 610–622 (2013).
Dafsari, H. S. et al. Subthalamic stimulation improves quality of life of patients aged 61 years or older with short duration of Parkinson’s disease. Neuromodulation 21, 532–540 (2018).
Antonini, A. et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr. Med. Res. Opin. https://doi.org/10.1080/03007995.2018.1502165 (2018).
Acknowledgements
The authors thank SciMentum, San Francisco, CA, USA for their help with drawing the figure.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Antonini, A., Jenner, P. Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14, 693–694 (2018). https://doi.org/10.1038/s41582-018-0083-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-018-0083-y
This article is cited by
-
Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review
Medicinal Chemistry Research (2024)
-
Current and novel infusion therapies for patients with Parkinson's disease
Journal of Neural Transmission (2023)
-
Aporphine and isoquinoline derivatives block glioblastoma cell stemness and enhance temozolomide cytotoxicity
Scientific Reports (2022)
-
Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway
Cellular and Molecular Neurobiology (2022)
-
Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells
Investigational New Drugs (2020)